Standout Papers

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physic... 2019 2026 2021 2023 475
  1. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019)
    Mark E. Robson, Nadine Tung et al. Annals of Oncology

Citation Impact

57 standout
Sub-graph 1 of 21

Citing Papers

The balance of STING signaling orchestrates immunity in cancer
2024 Standout
G-quadruplex DNA structure is a positive regulator of MYC transcription
2024 Standout
2 intermediate papers

Works of W. Li being referenced

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
2019 Standout
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
2015

Author Peers

Author Oncology PRM Molecular Biology Last Decade Papers Cites
W. Li 659 321 362 45 943
Karen Jui Lin Choo 3 16 9 15 371
R. M. Hunger 3 2 114 62 918
Leo S. Jensen 15 9 119 82 2.0k
Emanuela Manno 4 5 6 485
Mengjiao Ma 15 11 58 22 298

All Works

Loading papers...

Rankless by CCL
2026